Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder
- Conditions
- Female Sexual Arousal DisorderFemale Sexual Dysfunction (FSD)
- Interventions
- Drug: Placebo
- Registration Number
- NCT06651541
- Lead Sponsor
- Biozeus Biopharmaceutical S.A.
- Brief Summary
Evaluation of the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder
- Detailed Description
Female Sexual Arousal Disorder (FSAD) is defined as the recurrent inability to attain or maintain sufficient genital arousal during sexual activity. Therefore, a healthy blood flow is central to the physiological processes related to sexual arousal, leading to genital lubrication, warmth, and clitoral protrusion.
The vasculature and blood flow in vaginal tissue can be compromised due to natural aging and various risk factors, including cigarette smoking, alcohol abuse, lack of exercise, high-fat diets, hypertension, hypercholesterolemia, and diabetes mellitus. All these risk factors and conditions are highly prevalent among women and can lead to FSAD. BZ371A offers a potential solution by increasing blood flow in genital tissue through its unique mechanism of action, thereby restoring vascular homeostasis and the physiological processes related to sexual arousal in women.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Female
- Target Recruitment
- 140
- Women between the ages 21 and 65;
- Pre-menopausal or post-menopausal women may be included;
- May or may not be taking female sex hormones (estrogen with or without progesterone, or their derivatives);
- FSAD, defined as the inability, persistent or recurrent, to obtain or maintain until the conclusion of sexual activity an adequate genital response to sexual arousal (lubrication, warmth and enlargement of the clitoris);
- Women with FSAD who present marked suffering or interpersonal difficulties;
- Stable relationship for more than 6 months, with a sexually active partner;
- Ability to read and understand the Informed Consent Form (ICF) and to answer the questionnaires.
- Women who do not agree to use a contraceptive method and who have the capacity to become pregnant during the study;
- Women who do not agree to attempt sexual activity at least twice a week while taking the study medication;
- History of unresolved sexual trauma or abuse, that could interfere with participation or the results of the study;
- Diagnosis of vaginismus, genitopelvic pain/penetration disorder and/or sexual aversion disorder;
- Uncontrolled diabetes at screening visit (HbA1C > 10%);
- Prior spinal cord injury, with lower limb paralysis;
- History of abdominal or pelvic surgery that may have damaged pelvic nerves, including vulvectomy, colostomy, cytostomy, hysterectomy, or bladder suspension;
- Current testosterone use, or long-term testosterone use (such as chip) within the past 6 months;
- Patients with current depression, characterized by the use or need to use psychotropic drugs, including bupropion, lithium or neuroleptics;
- Presence of genital lesions that impair analysis of local adverse effects on the genitalia;
- Presence of diseases that cause excessive vaginal discharge, such as recurrent urinary tract infection, vaginal infection and pelvic inflammatory disease.
- Abnormal Papanicolaou test within the past 3 years;
- History of gynecological cancer (history of uterine dysplasia can be included, provided it has been properly treated for at least 6 months);
- History of pelvic irradiation;
- Use of topical medications in the genital region that may interfere with PSI assessment as well as their absorption or drug interaction, including vaginal estrogens, lubricants, spermicides, creams or gels, vaginal douches;
- History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patient with heart disease (including history of angina and/or heart failure) and nephropathies;
- Current use of nitrates, such as propatylnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®, Nitronal®, Tridil®) and isosorbitol dinitrate (Isocord®)
- ECG findings that are clinically symptomatic, or that, in the Investigator's judgment, are considered significant and pose a risk to the research volunteer's participation;
- Findings on laboratory tests that, in the Investigator's judgment, are considered significant and offer risk to the research volunteer's participation or may hinder the study analyses;
- TSH outside normal limits for age (participants with hypothyroidism on stable dose of medication, over 3 months, may be included);
- BP outside safe limits: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg or above 100 mmHg, except for situations such as "white coat" syndrome;
- Severe hypertension, considered to be the use of three or more antihypertensive drugs;
- Diseases that can cause clitoral priapism, such as sickle cell anemia, multiple myeloma or leukemia;
- History of clitoral priapism;
- Current relevant diarrhea, defined as duration over four weeks, association with abdominal pain or malabsorptive syndrome, or presence of mucus, pus, or blood in the stool;
- Pregnant or lactating;
- Current use of nitric oxide donors, guanylate cyclase stimulators (e.g. Riociguat), or 5- phosphodiesterase inhibitors (Sildenafil, Tadalafil, etc.);
- Any disease or condition or physical finding that the Investigator considers significant and that increases the risk of the research participant's participation or may interfere with the results, including serious debilitating diseases, presence of cancer, serious mental illness, persistent abuse of medication;
- Partners with significant erectile dysfunction, defined as the inability to maintain an erection to provide satisfactory sexual intercourse in most sexual encounters;
- Less than 3 valid sexual encounters, defined as a "yes" answer to question 7 of the FSEP, or use of less than 3 doses of PSI in the run-in period.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BZ371A group BZ371A The medication will be administered at least twice a week (according to demand), followed by sexual encounters, for 8 weeks Placebo Group Placebo The medication will be administered at least twice a week (according to demand), followed by sexual encounters, for 8 weeks
- Primary Outcome Measures
Name Time Method Efficacy in increasing arousal Baseline, 4 weeks and 8 weeks Evaluation of the efficacy of BZ371A in increasing arousal using Female Sexual Encounter Profile (FSEP) questionnaire. The study will evaluate number of "yes" answers to question 3 in the Female Sexual Encounter Profile (FSEP) questionnaire, divided by the number of valid attempts (question 7 of the FSEP).
The study will evaluate the increase in the FSEP score based on the baseline FSEP value, obtained before using the BZ371A. Thus, the higher the number of yes answers, the better the efficacy of the drug.
- Secondary Outcome Measures
Name Time Method Efficacy in increasing desire, lubrification, orgasm and arousal Baseline, 4 weeks and 8 weeks Evaluation of the success rate for desire, lubrification, orgasm and for arousal using Female Sexual Encounter Profile (FSEP). The number of successes for desire will be assessed using FSEP Question 2 / FSEP Question 7, for lubrication FSEP Question 4 / FSEP Question 7, for orgasm FSEP Question 5 / FSEP Question 7 and for the degree of arousal FSEP Question 6 / FSEP Question 7. For each question, the number of "yes" answers will be counted as success. Therefore, for each "no" answer the value will be 0 and for each "yes" answer the value will be 1.
Evaluation of the quality of female sexual encounters Baseline, 4 weeks and 8 weeks Evaluation based on the total score of the Female Sexual Encounter Profile (FSEP) questionnaire. The score ranges from 0 to 9. Therefore, the higher the score, the better the participant's sexual encounter.
Female Sexual Function Index (FSFI) Baseline, 4 weeks and 8 weeks Evaluation of the score for each domain (Desire, Arousal, Lubrication, Orgasm, Satisfaction, Pain) using the Female Sexual Function Index (FSFI) questionnaire. The score ranges from 2 to 36. Thus, the higher the score, the better the participant's sexual satisfaction.
Assessment of treatment satisfaction Baseline, 4 weeks and 8 weeks Response rate to the Global Assessment Question (GAQ), by the number of "yes" answers to the question about arousal and sexual pleasure.
Adverse effects report Baseline, 4 weeks, 8 weeks and 10 weeks after baseline Adverse effects evaluation of compound use and application
Physical examination of the genitalia Up to 60 days before baseline, 30 days before baseline, baseline, 4 weeks, 8 weeks and approximately 11 weeks Number of participants with abnormal physical exam findings in the applied region.
Change in systemic blood pressure From up to 60 days before Baseline, 30 days before Baseline, Baseline, 4 weeks, 8 weeks and, approximately, 10 weeks Change in Diastolic Blood Pressure and Systolic Blood Pressure
Change in Heart Rate (HR) From up to 60 days before Baseline, 30 days before Baseline, Baseline, 4 weeks, 8 weeks and, approximately, 11 weeks Change in Heart Rate
Basal chest electrocardiogram (ECG) From up to 60 days before baseline, baseline and 8 weeks after baseline Number of participants with abnormal electrocardiogram (ECG) findings.
Blood evaluation From up to 60 days before Baseline, baseline and 8 weeks after baseline Number of participants with abnormal laboratory test results
Urine evaluation From up to 30 days before baseline, baseline and 8 weeks after baseline Number of participants with abnormal laboratory test results
Trial Locations
- Locations (1)
Ambulatório Jenny Farias do Hospital das Clínicas da UFMG
🇧🇷Belo Horizonte, Brazil